# Liraglutide

## Saxenda inj 18mg/3mL

| TAH Drug Code      | [ISAX](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISAX)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in: **Adult** patients with an initial BMI of (1) 30 kg/m2 or higher (obese), or (2) 27 kg/m2 or higher (overweight) and having at least one weight-related comorbid condition (such as hypertension, type 2 diabetes mellitus, or dyslipidemia). **Pediatric** patients aged 12 years or older with body weight over 60 kg, and an initial BMI equivalent to 30 kg/m2 for adults (obese) based on international standards.                                                                                                                                                                                                                                                                                                                            |
| Dosing             | [Adults and Children >= 12 years old] Obesity, or overweight in the presence of at least one weight-related comorbidity: Initial, 0.6 mg subQ once daily for 1 week; increase weekly in increments of 0.6 mg/day until maintenance dosage of 3 mg once daily is reached.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Hypersensitivity to liraglutide or any component of the product. Personal or family history of medullary thyroid carcinoma. Personal of family history of multiple endocrine neoplasia syndrome type 2. Pregnancy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | [Common] Hypoglycemia (Adult, monotherapy, 7.1-12.6%; adult, combination therapy, 3.6-28.2%; pediatric, 15.2 to 21.2%), Constipation (Type 2 diabetes, 5-9.9%; weight management, 4.8-19.4%), Decrease in appetite (9-10%), Diarrhea (10-22.4%), Indigestion (4-9.6%), Nausea (Type 2 diabetes, 18-28.4%; weight management, 39.3-42.4%), Vomiting (Type 2 Diabetes, 6-15.7%; weight management, 34.4% (pediatric)), Headache (9.1-13.6%), Upper respiratory infection (6-9.5%) [Serious] Breast cancer (0.6%), C-cell hyperplasia of thyroid, Medullary thyroid carcinoma, Papillary thyroid carcinoma (0.2%), Cholecystitis (0.8% ), Cholelithiasis (1.15-2.2%), Colorectal cancer (0.2%), Pancreatic cancer, Pancreatitis (0.3-0.8%), Anaphylaxis, Suicidal, completed (Pediatric, 0.8%), Suicidal thoughts (0.3%), Acute renal failure, Angioedema |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| More Info          | [UpToDate](https://www.uptodate.com/contents/liraglutide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

